• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.

Sep 04, 2018 7:30am EDT

OncoSec to Present at H.C. Wainwright 20th Annual Global Investment Conference

Aug 31, 2018 8:00am EDT

OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor

Aug 28, 2018 8:00am EDT

OncoSec Enters Research Collaboration Agreement with UCLA and Roger S. Lo, M.D., Ph.D.

Aug 06, 2018 8:00am EDT

OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory

Jul 30, 2018 8:00am EDT

OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer

Jul 17, 2018 8:00am EDT

OncoSec Appoints Sara M. Bonstein as Chief Financial Officer and Chief Operating Officer

Jul 16, 2018 8:00am EDT

OncoSec Provides Outlook for Second Half of 2018

Jun 28, 2018 8:00am EDT

OncoSec Added to the Russell Microcap® Index

Jun 25, 2018 8:00am EDT

OncoSec Presents Update on PISCES/KEYNOTE-695 Phase 2b Registration-Directed Clinical Trial in Combination with Merck's KEYTRUDA® for Metastatic Melanoma at the ASCO 2018 Annual Meeting

Jun 04, 2018 8:00am EDT
RSS
  • Prev
    • 1...
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • 17
    • 18
    • 19
    • ...45
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    logo

    Sign Up for our mailing list to stay current on all of our exciting new research and developments.

    Get Email Alerts
    OncoSec’s investigational products have not been approved or cleared by the FDA.

    Links

    • About
    • Pipeline
    • Technology
    • Partnering
    • Patients
    • Media
    • Investors
    • Contact
    • KEYNOTE 695 CLINICAL TRIAL

    Contact

    New Jersey Headquarters
    24 N. Main St
    Pennington, NJ 08534

    R&D Laboratories
    3565 General Atomics Court #100
    San Diego, CA 92121

    p | 855.662.6732
    f | 858.430.3832

    Investors@OncoSec.com


    © 2022 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.